XYOTAX (paclitaxel poliglumex)
XYOTAX™ (pronounced Zi-o-taks) is a biologically-enhanced
chemotherapeutic that links paclitaxel, the active ingredient in
Taxol®, to
a biodegradable polyglutamate
polymer, which results in a new chemical
entity.
XYOTAX™ is intended to provide a potentially more effective
treatment by delivering more paclitaxel to the tumor cells. When
bound to
the polymer, the chemotherapy is rendered inactive, potentially
sparing normal tissue's exposure to high
levels of unbound, active chemotherapy and its associated toxicities.
Blood
vessels in tumor tissue, unlike blood vessels in normal tissue,
are porous to molecules like polyglutamate. Once inside the
tumor cell, enzymes metabolize the protein polymer, releasing
the paclitaxel
chemotherapy. Based on preclinical studies, it appears that
XYOTAX™ is preferentially trapped in the tumor blood vessels
allowing significantly more of the dose of chemotherapy to remain
in the
tumor.
XYOTAX™ Preclinical and Clinical Research
We are currently studying XYOTAX in a number
of clinical trials for the potential treatment of a variety of
cancers including
non-small cell lung (NSCLC) and ovarian cancer. Preclinical and clinical studies support that XYOTAX metabolism
by lung cancer cells may be influenced by estrogen which could
lead to enhanced release of paclitaxel and efficacy in women with
lung cancer over non-biologically enhanced chemotherapeutic agents.
|